--- title: "Sectra AB Secures Digital Pathology Expansion Contract with Guelph General Hospital" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275475434.md" datetime: "2026-02-10T14:30:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275475434.md) - [en](https://longbridge.com/en/news/275475434.md) - [zh-HK](https://longbridge.com/zh-HK/news/275475434.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275475434.md) | [繁體中文](https://longbridge.com/zh-HK/news/275475434.md) # Sectra AB Secures Digital Pathology Expansion Contract with Guelph General Hospital Sectra AB has announced that Guelph General Hospital signed a statement of work for the expansion of its digital pathology services with Sectra in May 2025. The project included validation testing in September 2025 and went live for clinical use on January 8, 2026. This implementation marks Guelph General Hospital as the first site in Canada to go live with Sectra’s Digital Pathology Module, utilizing the Sectra One Cloud enterprise imaging platform to support approximately 10,000 pathology exams annually. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sectra AB published the original content used to generate this news brief via Cision (Ref. ID: BITN\_\_\_\_20260209BIT8070) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ## 相关资讯与研究 - [Omeros Turns Corner With Novo Deal, YARTEMLEA Launch](https://longbridge.com/zh-CN/news/281666535.md) - [OMER S.p.A.: Resilient Fundamentals and Structural Growth Support Buy Rating Despite Softer FY26 Outlook](https://longbridge.com/zh-CN/news/281649119.md) - [](https://longbridge.com/zh-CN/news/281626394.md) - [Top NeurAxis Insiders Make Bold Moves With Fresh Stock Buys](https://longbridge.com/zh-CN/news/281670217.md) - [RBC Capital Reaffirms Their Buy Rating on Insulet (PODD)](https://longbridge.com/zh-CN/news/281669086.md)